호흡기 인터벤션 시장 - 업계 분석, 규모, 점유율, 성장, 동향 및 예측(2031년) - 제품별, 적응증별, 최종 사용자별, 지역별
Interventional Pulmonology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
상품코드:1496078
리서치사:Fairfield Market Research
발행일:2024년 06월
페이지 정보:영문 270 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 호흡기 인터벤션 시장 규모는 2024년까지 13억 달러에 이를 것으로 예상되고 있으며, 앞으로 현저한 성장을 이루려고 합니다. 이 시장은 5%의 연평균 복합 성장률(CAGR)로 확대되어 2031년에는 18억 5,000만 달러에 이를 전망입니다. 이 강력한 성장의 원동력은 만성 폐색성 폐질환(COPD)의 유병률 상승과 고급 진단·치료 옵션에 대한 수요 증가입니다.
COPD는 만성 기관지염과 천식과 같은 질병을 포함한 만성 및 진행성 질환으로 세계적으로 큰 건강 문제가되고 있습니다. 세계보건기구(WHO)에 따르면 2019년에는 323만명이 COPD로 사망해 세계에서 3번째로 많은 사인이 되고 있습니다. 특필해야할 것은 70세 미만의 COPD 관련 사망의 90% 가까이가 저·중소득국에서 발생하고 있는 것입니다. COPD의 이환율 증가는 개입적 폐 치료에 대한 수요를 증가시켜 시장 성장을 가속할 것으로 예상됩니다.
세계 인구의 고령화가 진행됨에 따라 호흡기 질환 및 기타 관련 질환을 가진 사람의 수가 증가하고 있습니다. 평균 수명이 늘어남에 따라 65세가 넘는 사람의 비율도 증가하여 호흡기 인터벤션 절차에 대한 수요가 증가하고 있습니다. 이러한 인구동태의 변화는 장기적인 시장 확대에 기여할 것으로 예상됩니다.
본 보고서에서는 세계의 호흡기 인터벤션 시장에 대해 조사했으며, 시장 개요와 함께 제품별, 적응증별, 최종 사용자별, 지역별 동향 및 시장 진출기업의 경쟁 동향 등을 제공합니다.
목차
제1장 주요 요약
제2장 시장 개요
시장 정의와 세분화
시장 역학
밸류체인 분석
Porter's Five Forces 분석
COVID-19의 영향 분석
우크라이나·러시아 분쟁의 영향
경제 개요
PESTLE 분석
제3장 가격 분석(2019-2023년)
제4장 세계의 호흡기 인터벤션 시장 전망(2019-2031년)
세계의 호흡기 인터벤션 시장 전망, 제품별, 금액(10억 달러), 수량(대)(2019-2031년)
세계의 호흡기 인터벤션 시장 전망, 적응증별, 금액(10억 달러), 수량(대)(2019-2031년)
세계의 호흡기 인터벤션 시장 전망, 최종 사용자별, 금액(10억 달러), 수량(대)(2019-2031년)
세계의 호흡기 인터벤션 시장 전망, 지역별, 금액(10억 달러), 수량(대)(2019-2031년)
The global interventional pulmonology market, projected to achieve revenues of US$ 1.3 billion by 2024, is poised for significant growth. With a compound annual growth rate (CAGR) of 5%, the market is expected to reach a valuation of US$ 1.85 billion by 2031. This robust growth is fueled by the increasing prevalence of chronic obstructive pulmonary disease (COPD) and the escalating demand for advanced diagnostic and treatment options.
Increasing COPD Incidence Driving Market Growth
COPD, a chronic and progressive condition encompassing disorders such as chronic bronchitis and asthma, is a major health concern globally. According to the World Health Organization (WHO), 3.23 million individuals died from COPD in 2019, making it the third most common cause of death worldwide. Notably, nearly 90% of COPD-related deaths in people under the age of 70 occur in low- and middle-income nations. The rising incidence of COPD is expected to increase the demand for interventional pulmonary procedures, thereby driving market growth.
Impact of Smoking on COPD Rates
The American Lung Association highlights that the majority of COPD cases are caused by smoking cigarettes. Current smokers are seven times more likely to develop COPD, while former smokers are five times more likely compared to non-smokers. The widespread use of tobacco and nicotine-based smoking products contributes significantly to lung health issues. This escalating demand for diagnosis and treatment options for lung illnesses is expected to boost the interventional pulmonology market.
Aging Population and Respiratory Disorders
The global population is aging, and the number of individuals with respiratory disorders and other associated conditions is rising. As life expectancy increases, the proportion of individuals over 65 also grows, leading to higher demand for interventional pulmonary procedures. This demographic shift is expected to contribute to market expansion over time.
Factors Driving Market Growth Over the Forecast Period
Increasing Healthcare Spending and Improving Healthcare Infrastructure
Enhanced healthcare infrastructure and increased healthcare expenditures by public bodies are supporting the adoption and use of advanced medical devices in healthcare facilities. This trend is expected to drive the demand for interventional pulmonology procedures. Emerging economies such as India, Brazil, and Mexico, which have high COPD patient populations, present significant opportunities for market growth. Economic development and rising disposable income in these regions are expected to secure the market's long-term viability.
Advancement in Technology
Technological advancements in interventional pulmonology devices are expected to enhance the outcomes of pulmonary procedures. Manufacturers are incorporating advanced unreactive materials, such as silicon coatings, to prevent microbial film formation on bronchoscopes. Additionally, extra-thin manufacturing processes and higher-resolution cameras are being used to improve bronchoscopy techniques. These innovations are expected to uplift the market.
Manufacturers are also developing insertion tubes that can be easily rotated to reduce practitioner stress and fatigue. The miniaturization of endoscopic equipment and the introduction of ultra-slim designs for observing thin bronchi are among the strategies being employed to improve device performance.
Rising Demand for Improved Bronchoscopy Techniques
Technological advancements in bronchoscopy are contributing to the growth of the global interventional pulmonology market. Improvements in electronics and microtechnology have led to safer and more accurate diagnoses of lung disorders, resulting in better patient outcomes. The demand for advanced bronchoscopy techniques is expected to drive market growth throughout the forecast period.
Challenges Facing the Interventional Pulmonology Market
Lack of Awareness Regarding Symptoms of Asthma and COPD
A significant challenge facing the market is the lack of awareness about the symptoms of asthma and COPD. Many individuals with respiratory illnesses remain undiagnosed and untreated, particularly in low-income countries. This lack of awareness is a major impediment to market growth.
Availability of Non-Invasive Options and Strict Regulations
The development of non-invasive diagnostic techniques, such as liquid biopsies and magnetic resonance spectroscopy, poses a challenge to the growth of the interventional pulmonology market. Additionally, stringent regulatory requirements, such as pre-market approval (PMA) for Class III devices by the FDA, add to the market's challenges. The rigorous approval processes and the need for clinical evidence for high-risk devices are hindering market expansion.
Associated Side Effects of Bronchoscopy Procedures
Bronchoscopy procedures carry risks such as contamination, infection, bleeding, breathing difficulties, and low blood oxygen levels. These complications reduce the adoption rates of bronchoscopy techniques. The advent of methicillin-resistant Staphylococcus aureus and other resistant bacteria has increased the likelihood of post-bronchoscopy infections, further limiting market growth.
Country-Wise Insights
Why is the U.S. Market Booming?
Increasing Prevalence of Asthma
In 2022, the U.S. accounted for approximately 90.7% of the North American interventional pulmonology market. According to the Asthma and Allergy Foundation of America, around 25 million people in the U.S. suffer from asthma, which corresponds to about 1 in every 13 individuals. This high prevalence of asthma is driving the demand for interventional pulmonology procedures.
Will Germany Be a Lucrative Market for Interventional Pulmonology Manufacturers?
Rising Cases of COPD
Germany holds an 18.3% market share in Europe. An estimated 10-12% of German adults over the age of 40 have COPD. By 2030, the number of COPD patients in Germany is expected to rise to 7.9 million from 6.8 million in 2010. Smoking and occupational air pollution are significant contributors to respiratory illnesses in the country, making COPD one of the most prevalent disorders.
How is China Emerging as a Prominent Market for Interventional Pulmonology?
Growing Geriatric Population
In 2022, China held a market share of about 52.8% of the East Asian interventional pulmonology market. WHO estimates indicate that China has one of the world's fastest-growing aging populations. By 2040, 28% of China's population is expected to be over 60. This large geriatric population, coupled with rising respiratory ailments, presents lucrative growth opportunities for the interventional pulmonology market.
